Scaling up for cell and gene therapies

Cell and gene therapies typically require a substantial number of cells per dose and as the number of diseases that can be targeted by contemporary cell and gene therapies expands from the initial suite of rare diseases in which these therapeutic modalities had their breakthrough, the number of doses required is set to skyrocket. Traditional 2D methods of production cannot provide an adequate cell yield to keep pace with the increasing demand, making bioreactor scale up a necessity.

However, there are several challenges to scaling up bioreactors that are limiting the progression of allogeneic cell therapies. These challenges include unfavorable hydrodynamic conditions, media cost, and lack of robust, scalable bioprocesses with reproducible results. This Spotlight, in partnership with PBS Biotech will examine the different strategies that can be used to address these challenges and optimize scale up for cell and gene therapies in a cost-effective manner.

This feature was produced in association with PBS Biotech.